NCT01748539已完成2 期
A Randomized, Double-blind, Placebo-controlled Parallel Group Study in Subjects With Plaque Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 140
- 试验地点
- 1
- 主要终点
- Percent improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12
研究概览
简要总结
This study is designed to evaluate the efficacy and safety of KHK4827 in subjects with moderate to severe plaque psoriasis in a randomized, double-blind, placebo-controlled, parallel group study. Pharmacokinetics of KHK4827 will also be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 20 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has had stable moderate to severe plaque psoriasis for at least 6 months.
- •Subject has received at least one previous phototherapy or systemic psoriasis therapy or has been a candidate to receive phototherapy or systemic psoriasis therapy in the opinion of the investigator.
- •Subject has involved BSA ≥ 10% and PASI ≥ 12 at screening and at baseline.
排除标准
- •Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced, or medication-exacerbated psoriasis.
- •Evidence of skin conditions at the time of the screening visit (eg, eczema) that would interfere with evaluations of the effect of investigational product on psoriasis.
- •Subject has any active Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher infection
- •Subject has a significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol.
- •Subject has used the following therapies within 14 days of the first dose: topical calcineurin inhibitors including tacrolimus
- •, topical vitamin A, activated form D3 or activated form D3 analogue preparations, weak through strong topical steroids (excluding application on the scalp, axillae, and groin)
- •Subject has used the following therapies within 28 days of the first dose: any other systemic psoriasis therapy (eg, vitamin A, calcineurin inhibitors, methotrexates, steroids), UVA therapy (with or without psoralen), very strong or strongest topical steroid, tar therapy
- •Subject has used the following therapies within 3 months of the first dose: adalimumab, etanercept, infliximab, or live vaccines
- •Subject has used ustekinumab within 6 months of the first dose
- •Subject has previously used an anti-interleukin-17 biologic therapy
研究组 & 干预措施
KHK4827 70mg SC
Experimental
干预措施: KHK4827 (Drug)
KHK4827 140mg SC
Experimental
干预措施: KHK4827 (Drug)
KHK4827 210mg SC
Experimental
干预措施: KHK4827 (Drug)
Placebo SC
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Percent improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12
时间窗: 12 weeks
次要结局
- PASI 75 at Week 12(12 Weeks)
- PASI 50, 90 and 100 at Week 12(12 weeks)
- Static physician's global assessment (sPGA) of "clear or almost clear (0 or 1)" at Week 12(12 Weeks)
- sPGA of "clear (0)" at Week 12(12 weeks)
- Body surface area involvement (BSA) of lesion at Week 12(12 weeks)
- American College of Rheumatology (ACR) 20% response (only in subjects with psoriasis arthritis)at week 12(12 weeks)
- Incidence and types of adverse events and adverse reactions(12 weeks)
- Profiles of Pharmacokinetics(12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in KoreaModerate to Severe Plaque PsoriasisNCT02982005Kyowa Kirin Korea Co., Ltd.62
已完成
2 期
A Comparative Study of KHK6188Postherpetic NeuralgiaNCT01544296Kyowa Kirin Co., Ltd.42
已完成
2 期
A Phase IIa Study of KHK4563Uncontrolled and Suspected Eosinophilic AsthmaNCT01412736Kyowa Kirin Co., Ltd.106
已完成
3 期
An Open-label, Non-controlled Study of KHK4827 in Subjects With PsoriasisPsoriasisNCT01782937Kyowa Kirin Co., Ltd.30
撤回
2 期
A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative ColitisUlcerative ColitisNCT04898348KoBioLabs